Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2/3 Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

NCT07109414 is registered in ClinicalTrials.gov with Novita Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07109414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07109414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2/3 Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Lead sponsor
Novita Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 29, 2025
Completion date
October 24, 2029
Enrollment
380 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant ovarian cancer